# Ingevity Corp: overview

NGVT · NYSE · CIK 1653477 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ngvt.md) · [Financials](/companies/ngvt/financials.md) · [Filings](/companies/ngvt/filings.md) · [Insiders](/companies/ngvt/insiders.md)

Latest reported revenue: [$314.1m](/filings/0001653477-26-000047.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001653477-26-000047).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [334](/filings/0001653477-25-000127.md) | [263 d](/filings/0001653477-26-000014.md) | [248](/filings/0001653477-26-000035.md) | [332](/filings/0001653477-26-000047.md) | [333](/filings/0001653477-25-000127.md) | [255 d](/filings/0001653477-26-000014.md) | [258](/filings/0001653477-26-000035.md) | [314](/filings/0001653477-26-000047.md) |
| Gross margin | % | [39.4%](/filings/0001653477-25-000127.md) | [37.9% d](/filings/0001653477-26-000014.md) | [45.1%](/filings/0001653477-26-000035.md) | [38.6%](/filings/0001653477-26-000047.md) | [40.2%](/filings/0001653477-25-000127.md) | [34.4% d](/filings/0001653477-26-000014.md) | [45.1%](/filings/0001653477-26-000035.md) | [44.3%](/filings/0001653477-26-000047.md) |
| Operating margin | % | [33.0%](/filings/0001653477-24-000100.md) | [52.2% d](/filings/0001653477-26-000014.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(32.1%)](/filings/0001653477-25-000127.md) | [6.3% d](/filings/0001653477-26-000014.md) | [8.3%](/filings/0001653477-26-000047.md) | [(44.2%)](/filings/0001653477-26-000047.md) | [13.1%](/filings/0001653477-25-000127.md) | [(33.2%) d](/filings/0001653477-26-000014.md) | [23.2%](/filings/0001653477-26-000047.md) | [11.2%](/filings/0001653477-26-000047.md) |
| Diluted EPS | $ per share | [(2.94)](/filings/0001653477-25-000127.md) | not reported | [0.56](/filings/0001653477-26-000035.md) | [(4.02)](/filings/0001653477-26-000047.md) | [1.18](/filings/0001653477-25-000127.md) | not reported | [1.66](/filings/0001653477-26-000035.md) | [1.00](/filings/0001653477-26-000047.md) |
| Free cash flow | $m | [28.5 d](/filings/0001653477-25-000127.md) | [39.6 d](/filings/0001653477-26-000014.md) | [15.4](/filings/0001653477-26-000035.md) | [66.8 d](/filings/0001653477-26-000047.md) | [118 d](/filings/0001653477-25-000127.md) | [73.5 d](/filings/0001653477-26-000014.md) | [(12.3)](/filings/0001653477-26-000035.md) | [(24.1) d](/filings/0001653477-26-000047.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,392](/filings/0001653477-24-000009.md) | [1,668](/filings/0001653477-25-000015.md) | [1,216](/filings/0001653477-26-000014.md) | [1,200](/filings/0001653477-26-000014.md) | [1,168](/filings/0001653477-26-000014.md) |
| Gross margin | % | [36.9%](/filings/0001653477-24-000009.md) | [34.2%](/filings/0001653477-25-000015.md) | [36.6%](/filings/0001653477-26-000014.md) | [38.7%](/filings/0001653477-26-000014.md) | [39.5%](/filings/0001653477-26-000014.md) |
| Operating margin | % | [30.3%](/filings/0001653477-24-000009.md) | [27.1%](/filings/0001653477-25-000015.md) | [34.8%](/filings/0001653477-26-000014.md) | [35.5%](/filings/0001653477-26-000014.md) | [35.9%](/filings/0001653477-26-000014.md) |
| Net margin | % | [8.5%](/filings/0001653477-24-000009.md) | [12.7%](/filings/0001653477-25-000015.md) | [(0.4%)](/filings/0001653477-26-000014.md) | [(35.9%)](/filings/0001653477-26-000014.md) | [(14.3%)](/filings/0001653477-26-000014.md) |
| Diluted EPS | $ per share | [2.95](/filings/0001653477-24-000009.md) | [5.50](/filings/0001653477-25-000015.md) | [(0.15)](/filings/0001653477-26-000014.md) | [(11.85)](/filings/0001653477-26-000014.md) | [(4.61)](/filings/0001653477-26-000014.md) |
| Free cash flow | $m | [190](/filings/0001653477-24-000009.md) | [171](/filings/0001653477-25-000015.md) | [95.3](/filings/0001653477-26-000014.md) | [51.0](/filings/0001653477-26-000014.md) | [274](/filings/0001653477-26-000014.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ngvt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $400.5m | 5,364,204 |  | Added +66,489 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $177.5m | 2,376,803 |  | Added +200,072 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $117.3m | 1,571,127 |  | Reduced −10,744 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $111.8m | 1,497,321 |  | Added +38,086 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $94.9m | 1,270,958 |  | Reduced −161,608 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $80.3m | 1,075,514 |  | Reduced −418,778 |
| [SEGALL BRYANT & HAMILL, LLC](/funds/1006378.md) | 2026-06-30 | $78.7m | 1,054,605 |  | Reduced −54,443 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $74.1m | 992,049 |  | Reduced −163,323 |
| [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $72.7m | 974,107 |  | Reduced −17,909 |
| [ROYCE & ASSOCIATES LP](/funds/906304.md) | 2026-06-30 | $70.2m | 940,417 |  | Added +56,890 |

## Recent filings

[All 657 filings](/companies/ngvt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 20:21 ET | [10-Q](/filings/0001653477-26-000047.md) | Quarterly report, period 2026-06-30 | 0001653477-26-000047 |
| 2026-07-29 | 21:18 ET | [8-K](/filings/0001653477-26-000044.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001653477-26-000044 |
| 2026-06-24 | 20:50 ET | [8-K](/filings/0001653477-26-000037.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001653477-26-000037 |
| 2026-05-07 | 20:26 ET | [10-Q](/filings/0001653477-26-000035.md) | Quarterly report, period 2026-03-31 | 0001653477-26-000035 |
| 2026-05-06 | 20:35 ET | [8-K](/filings/0001653477-26-000031.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001653477-26-000031 |
| 2026-05-04 | 20:27 ET | [8-K](/filings/0001653477-26-000028.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001653477-26-000028 |
| 2026-04-15 | 20:38 ET | [8-K](/filings/0001653477-26-000021.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001653477-26-000021 |
| 2026-03-30 | 10:30 ET | [8-K](/filings/0001104659-26-036423.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001104659-26-036423 |
| 2026-03-17 | 20:25 ET | [DEF 14A](/filings/0001104659-26-029507.md) | Proxy statement, period 2026-04-29 | 0001104659-26-029507 |
| 2026-02-26 | 21:23 ET | [10-K](/filings/0001653477-26-000014.md) | Annual report, period 2025-12-31 | 0001653477-26-000014 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001653477-26-000014.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/3d8209fc-351e-4498-b9c2-fa8939fa0d11)

## About the filer

- CIK: 1653477
- Tickers: NGVT
- Exchange: NYSE
- SIC code: 2800 Chemicals & Allied Products
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.